Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Statens Serum Institut
DescriptionRecombinant subunit vaccine containing a fusion protein of tuberculosis antigens 85B and ESAT-6 formulated with the IC31 adjuvant
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationTuberculosis
Indication DetailsVaccinate against tuberculosis (TB) infection
Regulatory Designation
PartnerValneva SE

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today